nor-BNI

Norbinaltorphimine (nor-BNI) is a bivalent opioid antagonist comprising two naltrexone-derived pharmacophores linked through a pyrrole spacer, originally synthesized in 1987 by Portoghese, Lipkowski, and Takemori at the University of Minnesota as the first highly selective kappa opioid receptor (KOR) antagonist. The compound binds the KOR with low-nanomolar affinity (Ki approximately 1.8 to 4 nM), demonstrating 10- to 27-fold selectivity over mu and delta opioid receptors, and exhibits no clinically meaningful affinity for non-opioid receptors or transporters with the exception of weak alpha-2C adrenoceptor binding (Ki approximately 630 nM). The defining pharmacological feature of nor-BNI, and the property that has sustained three decades of research interest, is its extraordinary duration of action: a single systemic dose produces kappa antagonism that develops over 2 to 4 hours, reaches plateau, and persists for 14 to 21 days in rodents and up to several weeks in nonhuman primates, despite plasma clearance occurring within hours of administration.

The mechanistic basis for this prolonged action was elucidated principally by the Bhargava, Bruchas, and Chavkin laboratories, who demonstrated that nor-BNI acts as a collateral agonist at the c-Jun N-terminal kinase (JNK) pathway through a pertussis toxin-insensitive, G-protein-independent mechanism. JNK activation triggers de novo protein synthesis (including upregulation of the scaffolding protein 14-3-3 gamma) that produces a sustained structural change in the KOR signaling complex, selectively disrupting G-alpha-i-mediated signaling while sparing ERK activation. This mechanism is distinct from irreversible covalent receptor alkylation and from simple slow dissociation kinetics; recovery requires new receptor protein synthesis and occurs over approximately 14 days in rodents. The Bhargava and Bhargava (2019) demonstration that repeated low-dose administration (0.1 mg/kg daily) produces cumulative receptor inactivation equivalent to a single 10 mg/kg bolus establishes a dose-reduction paradigm with potential clinical translational relevance.

The preclinical pharmacology of nor-BNI spans mood, stress resilience, and addiction. In the social defeat stress model, nor-BNI pretreatment blocks stress-induced analgesia, reduces immobility in defeat postures, and prevents stress-induced potentiation of cocaine conditioned place preference. Nor-BNI attenuates stress-induced reinstatement of nicotine, cocaine, and ethanol seeking while leaving drug-primed reinstatement intact, consistent with selective engagement of the dynorphin/KOR stress axis rather than direct reward circuitry. In the forced swim test and tail suspension test, nor-BNI produces antidepressant-like reductions in immobility. These findings collectively position KOR antagonism as a therapeutic strategy for stress-related psychiatric disorders, and nor-BNI as the foundational pharmacological tool that validated the approach.

Nor-BNI itself has not entered human clinical trials. Its physicochemical properties (high molecular weight, low brain penetration with Kp,uu,brain less than 0.007, bivalent structure) and regulatory classification (DEA Schedule II as a noroxymorphone derivative in the United States) limit its clinical translatability. The clinical translation of KOR antagonism has proceeded through structurally distinct, orally bioavailable, short-acting compounds: aticaprant (CERC-501/LY2456302), navacaprant (BTRX-335140/NMRA-140), and JDTic, all of which owe their mechanistic rationale to the foundational nor-BNI preclinical literature. Aticaprant has completed Phase 2 trials in major depressive disorder with positive efficacy signals as adjunctive therapy to SSRIs/SNRIs; navacaprant is in Phase 3 development for treatment-resistant depression.

This monograph documents the chemistry, synthesis, and bivalent pharmacophore design of nor-BNI; the JNK-mediated mechanism of long-lasting receptor inactivation; the comprehensive preclinical pharmacology across stress, mood, and addiction models; the pharmacokinetic-pharmacodynamic dissociation that defines the compound; sourcing, reconstitution, and handling considerations for laboratory use; stack interactions; adverse-event and safety signal from preclinical studies; and a structured comparative assessment of five KOR antagonist candidates (aticaprant, navacaprant, JDTic, GNTI, 5'-guanidinonaltrindole) against nor-BNI on five competency standards.